Is Cannabis Legal in Greece? Medical-Only Rules Explained

Photo via Pexels.

Ask around Athens and you'll hear conflicting things: that cannabis is legal now, that it's still a crime, that you can buy hemp flower at a kiosk, that Greece is becoming some kind of Mediterranean cannabis exporter. All of these claims have a kernel of truth, which is exactly the problem. Recreational cannabis is illegal in Greece, full stop. Medical cannabis is legal, but only through a prescription tied to a tightly controlled domestic supply chain that took years to actually produce a product patients could pick up at a pharmacy. And as of May 2026, there's a new wrinkle that's thrown a lot of outdated coverage into disarray: Greece banned the retail sale of dried hemp flower entirely, right around the same time its medical cannabis market was projected to hit $46.8 million for the year.

The timing makes the whole picture look contradictory if you don't separate the pieces. It isn't contradictory once you do. Personal possession, medical prescriptions, cultivation licensing, and hemp flower retail are four distinct legal categories in Greece, governed by different statutes, enforced by different agencies, and moving in different directions. One track is tightening. The other is expanding into an export industry. This piece walks through each layer so you know what's actually legal, what's merely tolerated in courtrooms, and what will get you prosecuted.

Personal Possession: Still a Criminal Offense

Photo via Unsplash.

The backbone of Greek drug law is Law 4139/2013, the Narcotic Drugs Code, and Article 29 is the part that matters if you're asking whether you can carry a joint without consequence. The answer is no -- personal-use possession is classified as a misdemeanor, not a mere infraction, and it carries a maximum penalty of five months' imprisonment. In practice, Greek courts routinely suspend that sentence for first-time offenders or convert it into a fine, which has led to a persistent myth that possession is effectively decriminalized. It isn't. The conviction still goes on record, and the leniency is discretionary, not guaranteed.

Growing a handful of plants for your own use falls under the same umbrella as simple possession rather than being bumped up to a trafficking charge, which is a meaningful distinction if you're comparing Greece to countries that treat any cultivation as supply. But don't mistake that for official tolerance -- it just means the charge and penalty track mirror possession rather than the far harsher trafficking statute.

That harsher statute is where Greek law gets genuinely severe. Trafficking and supply offenses carry a minimum of eight years in prison and fines that can run up to EUR 300,000. The line between personal cultivation and trafficking often comes down to plant count, apparent intent, and whether prosecutors believe product was headed for sale -- factors that leave real discretion in the hands of police and courts rather than a bright-line rule written into statute.

The practical takeaway for anyone weighing their legal exposure in Greece: there is no decriminalized gray zone here the way there is in some neighboring EU states with civil-fine systems for small amounts. A valid medical prescription is the only legally protected way to possess and use cannabis in the country. Everything else runs through the criminal code, with judicial leniency as a possibility, not a guarantee.

How Medical Legalization Actually Happened

Photo by OsloMetX via Pixabay.

Greece's medical cannabis framework didn't arrive all at once. The starting point was June 2017, when lawmakers legalized medical cannabis in principle, but the structure that actually governs the industry came a year later with Law 4523/2018, introduced March 2, 2018. That statute set up the legal basis for domestic cultivation aimed at both patient supply and export -- a dual purpose that shapes nearly every rule that followed.

The operational details landed in Joint Ministerial Decree No. 51483/700/Φ.15, issued in May 2018, which spelled out how cultivation and processing licenses would actually work. The decree requires licensed companies to be vertically integrated, meaning a single operator has to control cultivation, processing, and the chain between them rather than splitting those functions across separate businesses. Licenses are also nontransferable, so a company can't acquire a cultivation permit and then sell or lease it to another operator down the line. That structure was clearly designed to keep the supply chain traceable and consolidated under accountable operators rather than a fragmented patchwork of growers and processors.

Products coming out of this system aren't treated as a wellness category or a supplement -- they're regulated as finished pharmaceuticals, which means they need full marketing authorization from EOF, the National Organization for Medicines, before they can reach a pharmacy shelf. That's a meaningfully higher bar than the registration requirements many countries apply to CBD products or even some medical cannabis programs elsewhere in Europe.

Getting to that point also requires clearing a two-step licensing process at the operator level. Companies need both an establishment approval and a separate operational license, and both are jointly issued by three ministries: Development and Investment, Health, and Rural Development and Food. That interagency sign-off is part of why Greece's program moved more slowly than the headlines from 2017 and 2018 suggested it would.

Why It Took Years for Patients to Fill a Prescription

Legalizing something on paper and making it available at a pharmacy counter turned out to be two very different timelines in Greece, and the gap between them is worth understanding before you assume any country's cannabis headlines translate into same-day access.

Article 71 of Law 4864/2021 banned medical cannabis imports outright, which meant that everything sold in Greek pharmacies had to be grown and processed domestically -- no bridging the gap with product from Canada, the Netherlands, or Israel while local cultivation ramped up. That single provision explains most of the delay. Building compliant cultivation and processing facilities from scratch, then getting EOF marketing authorization for finished products, takes years, not months.

For a long stretch, Tikun Olam was the only approved supplier in the country, effectively functioning as a monopoly while the domestic production base slowly scaled up. That changed in March 2025, when Curity Pharma received its operational cultivation license, becoming the second domestic producer and introducing at least a measure of competition into what had been a single-supplier market.

Here's the detail that surprises people who assume Greece's cannabis program dates to 2017: patients could not actually fill a cannabis prescription at a Greek pharmacy until February 2024. That's a six-and-a-half-year gap between legalization on paper and a patient walking out of a pharmacy with product in hand. It's a useful case study in how regulatory infrastructure -- import bans, manufacturing certification, marketing authorization, licensing bottlenecks -- can hold up access long after a law technically takes effect. Anyone evaluating a country's cannabis legality should ask not just when something became legal, but when it became available.

The 2026 Hemp Flower Ban -- and What It Doesn't Touch

Photo via Unsplash.

May 2026 brought the development that's been generating the most confused coverage: Law 5302/2026, which amended the Narcotic Drugs Code to strip dried hemp flower of its prior status as a raw agricultural product. The practical effect is blunt -- retail sale and supply of dried hemp flower directly to consumers is now banned outright in Greece, regardless of the product's THC content. A shop that previously sold low-THC hemp flower as a legal agricultural good can no longer do so, full stop.

The penalties attached to that ban aren't symbolic. Violations can draw fines up to EUR 100,000 and prison terms of up to five years, putting unauthorized hemp flower retail in a penalty bracket that signals Greek authorities are treating this as a serious enforcement priority, not a technicality.

At the same time, the same legislative package moved in a direction that looks, on its face, more permissive. Article 43 raised the industrial-hemp THC threshold from 0.2% to 0.3%, bringing Greece in line with the broader EU hemp standard that most member states have already adopted. That change applies to industrial hemp cultivation and processing -- fiber, seed, extract production -- not to flower sold directly to consumers, which remains banned regardless of how low its THC content sits.

EOF stepped in on May 28, 2026 to draw a clear boundary around what the new law does and doesn't touch: finished medicinal cannabis products, meaning the prescription flower and pharmaceutical preparations patients access through the medical program, are entirely outside the scope of this ban. A patient with a valid prescription is unaffected by any of this. The law is squarely aimed at the unregulated consumer hemp flower market that had been operating in a legal gray zone.

One housekeeping note for anyone researching this online: a number of explainer articles published around this same period still cite the old 0.2% THC threshold as current law. That figure is outdated as of Article 43's passage, and readers relying on those pieces should treat them as stale rather than authoritative.

Greece's Bet on Becoming a Southern European Export Hub

Strip away the compliance detail and Greece's medical cannabis sector tells a growth story. The market was valued at $32 million in 2025, with projections putting it at $46.8 million for 2026 -- roughly 46% growth in a single year, driven by expanding patient access following the February 2024 pharmacy milestone and the arrival of a second domestic producer.

There's a certain irony in how the domestic-only production rule has aged. Article 71's import ban was originally framed as protectionist policy, designed to force the buildout of local cultivation and processing capacity rather than let Greece become a pass-through market for foreign product. Years later, that same rule has left Greece with certified cultivation infrastructure that doubles neatly as an export base -- the country built the production capacity it needed to supply itself, and that capacity now exceeds domestic demand.

Tikun Olam and Curity Pharma are the two companies currently operating under the vertically integrated model the law requires, each controlling cultivation, processing, and distribution under a single nontransferable license. That structure, while slow to stand up, gives both operators tight quality control and a clean regulatory paper trail -- exactly what's needed to sell into other EU markets with their own strict pharmaceutical import standards.

Greece also has structural advantages that go beyond regulation. Its climate supports outdoor and greenhouse cultivation at lower energy cost than growers relying on indoor facilities face, and land and labor costs run meaningfully below markets like Germany or the Netherlands. That combination -- regulatory compliance plus a cost structure built for export -- is precisely what's made Southern European countries like Greece, Portugal, and Malta attractive to cannabis companies looking to supply the broader EU medical market rather than just their home country.

Whether Greece actually becomes a serious export hub depends largely on licensing pace. Curity Pharma's March 2025 approval suggests the ministries are willing to add producers rather than lock the market at two, and additional licenses would meaningfully deepen the export pipeline. That's the detail worth watching over the next year or two.

Put the pieces together and Greece comes into focus as one of Europe's stricter medical-only frameworks, not a loophole-ridden gray market some online coverage makes it out to be. Recreational use carries real criminal exposure under Article 29 of the Narcotic Drugs Code, with no civil-fine decriminalization to soften the edges the way some neighboring EU states offer. Even patients who had every legal right to use cannabis under the 2017-2018 reforms spent years waiting for the supply chain to catch up to the statute -- a six-and-a-half-year gap between legalization and an actual prescription filled at a pharmacy counter.

The 2026 hemp flower ban reinforces that this is a government comfortable tightening consumer-facing rules even as it expands the licensed industry on the other side of the ledger. Dried flower retail is now closed off entirely, penalties for violating that ban are substantial, and yet the medical program keeps growing toward that projected $46.8 million valuation, with a second licensed producer now online and more possibly coming. Two tracks, moving in opposite directions, inside the same legal system.

If there's one practical point worth carrying away from all this, it's that Greece doesn't extend the kind of quiet tolerance for personal cannabis use that travelers sometimes assume applies across the EU. Possession remains a prosecutable misdemeanor regardless of what's legal in Spain, Germany, or Malta, and courts' tendency to suspend first-time sentences is a matter of judicial discretion, not legal right. Anyone visiting or living in Greece should plan around that reality -- and given how quickly the regulatory detail has shifted just in the past year, it's worth checking current EOF guidance directly rather than trusting an explainer article that might already be a year out of date.

Browse our seed collection.